Testing NNC0487-0111 for weight loss in adults with obesity
Tests a once-weekly injection against a placebo in adults with obesity.
Plain-language title generated from the registry record
Registry title: AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Key facts
- Where
- Amarillo, Arlington, Chapel Hill, Charleston, City of Saint Peters, Conyers, Cumberland, Dallas, Forney, Greensboro, Indianapolis, Miramar, New York, Newport News, North Charleston, Orlando, Philadelphia, Renton, Simpsonville, Skokie, Wilmington, and Winchester, United StatesSee the 22 sites
- Phase
- Phase 3
Where in United States
- Amarillo Medical SpecialistsAmarillo, United StatesTaking people
- Washington Cntr Weight MgmtArlington, United StatesTaking people
- UNC Eastowne Medical OfficeChapel Hill, United StatesTaking people
- Medical Uni of SC CharlestonCharleston, United StatesTaking people
- StudyMetrix Research, LLCCity of Saint Peters, United StatesTaking people
- Hope Clin Res & WellnessConyers, United StatesTaking people
- Clinical Res CollaborativeCumberland, United StatesTaking people
- Velocity Clinical Res-DallasDallas, United StatesTaking people
- Care United Research, LLCForney, United StatesTaking people
- PharmQuest Life Sciences LLCGreensboro, United StatesTaking people
- Midwest Inst For Clin ResIndianapolis, United StatesTaking people
- South Broward Research LLCMiramar, United StatesTaking people
- New York Gastroenterology AssociatesNew York, United StatesTaking people
- Health Res of Hampton RoadsNewport News, United StatesTaking people
- Coastal Carolina Research CtrNorth Charleston, United StatesTaking people
- Clinical Neuroscience SolutionOrlando, United StatesTaking people
- UPA Ctr Weight and Eating DisPhiladelphia, United StatesTaking people
- Rainier Clin Res Ctr IncRenton, United StatesTaking people
- Hillcrest Clinical ResearchSimpsonville, United StatesTaking people
- Endeavor HealthSkokie, United StatesTaking people
- Accellacare and KDCILM, LLCWilmington, United StatesTaking people
- Selma Medical AssociatesWinchester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07339423EU 2024-520440-42-00
- Record updated
- 24 September 2026
- Original description
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Inclusion: Male or female (sex at birth); Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records; HbA1c ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.